| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Process | STA Standard |
| ID number | 3935 |
Provisional Schedule
| Expected publication | 15 November 2023 |
Project Team
| Project lead | Thomas Feist |
Email enquiries
- If you have any queries please email TATeam1@nice.org.uk
| External Assessment Group | School of Health and Related Research (ScHARR), University of Sheffield |
Stakeholders
| Companies sponsors | Daiichi Sankyo |
| Others | Department of Health and Social Care |
| NHS England | |
| Welsh Government | |
| Patient carer groups | Breast Cancer Now |
| METUP UK | |
| Professional groups | Association of Cancer Physicians |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Comparator companies | Eisai |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary (BNF) | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Institute of Cancer Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 05 September 2023 | Committee meeting: 1 |
| 06 January 2023 | Invitation to participate |
| 20 October 2022 - 17 November 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 20 October 2022 | In progress. Scoping commenced. |
For further information on our processes and methods, please see our CHTE processes and methods manual